top of page

Reproductive & Endocrine Systems

Aldosterone and renin regulation

Core Principle of Aldosterone and Renin Regulation
🧷 The renin-angiotensin-aldosterone system (RAAS) is the body's primary mechanism for maintaining blood pressure, intravascular volume, and electrolyte homeostasis.
🧷 Renin, secreted by juxtaglomerular cells in response to decreased renal perfusion, initiates a cascade that ultimately produces aldosterone from the adrenal zona glomerulosa.
🧷 Aldosterone acts on principal cells of the cortical collecting duct to increase Na⁺ reabsorption and K⁺ secretion, thereby expanding intravascular volume and raising blood pressure.
🧷 This system operates through negative feedback: increased blood pressure and volume suppress renin release, creating a self-limiting regulatory loop.
Solid White Background
Renin Release: The Three Primary Triggers
📍 Decreased renal perfusion pressure: Baroreceptors in the afferent arteriole detect reduced stretch → stimulate juxtaglomerular cells to release renin.
📍 Sympathetic activation: β₁-adrenergic receptors on juxtaglomerular cells respond to norepinephrine → direct stimulation of renin release.
📍 Decreased NaCl delivery to the macula densa: Low Na⁺ and Cl⁻ at the distal tubule signals volume depletion → macula densa releases prostaglandins and nitric oxide → paracrine stimulation of adjacent juxtaglomerular cells.
📍 Board pearl: All three mechanisms converge on the same endpoint — renin release — allowing the kidney to respond to various forms of volume depletion.
Solid White Background
The RAAS Cascade: From Renin to Aldosterone
🔹 Renin cleaves angiotensinogen (produced by the liver) → angiotensin I (a decapeptide with minimal biological activity).
🔹 Angiotensin-converting enzyme (ACE), primarily in pulmonary capillaries, converts angiotensin I → angiotensin II (an octapeptide).
🔹 Angiotensin II binds AT₁ receptors on adrenal zona glomerulosa cells → stimulates aldosterone synthesis and release.
🔹 Angiotensin II also causes direct vasoconstriction, stimulates ADH release, increases thirst, and enhances proximal tubule Na⁺ reabsorption — all working synergistically to restore blood pressure.
🔹 Board pearl: ACE also degrades bradykinin; ACE inhibitors therefore increase bradykinin levels, contributing to their side effect of dry cough.
Solid White Background
Aldosterone Synthesis in the Zona Glomerulosa
⭐ Cholesterol → pregnenolone (via cholesterol desmolase, the rate-limiting step) → progesterone → 11-deoxycorticosterone → corticosterone → aldosterone.
⭐ The final step, corticosterone → aldosterone, requires aldosterone synthase (CYP11B2), which is uniquely expressed in the zona glomerulosa.
⭐ This enzyme performs both 18-hydroxylation and 18-oxidation, converting corticosterone to aldosterone in two sequential reactions.
⭐ Board distinction: The zona glomerulosa lacks 17α-hydroxylase, preventing it from producing cortisol or androgens — it can only produce mineralocorticoids.
Solid White Background
Aldosterone's Molecular Mechanism of Action
✅ Aldosterone diffuses into principal cells and binds the mineralocorticoid receptor (MR), a nuclear receptor that acts as a transcription factor.
✅ The aldosterone-MR complex translocates to the nucleus → increases transcription of epithelial sodium channel (ENaC), Na⁺/K⁺-ATPase, and ROMK (K⁺ channel).
✅ ENaC insertion on the apical membrane increases Na⁺ reabsorption; Na⁺/K⁺-ATPase on the basolateral membrane drives the Na⁺ gradient; ROMK allows K⁺ secretion.
✅ 11β-hydroxysteroid dehydrogenase type 2 protects the MR by converting cortisol → cortisone (inactive), preventing cortisol from overwhelming aldosterone signaling.
✅ Board pearl: Licorice inhibits 11β-HSD2, allowing cortisol to activate MR → apparent mineralocorticoid excess.
Solid White Background
Potassium as a Direct Aldosterone Stimulus
🧠 Hyperkalemia directly depolarizes zona glomerulosa cells → opens voltage-gated calcium channels → Ca²⁺ influx → stimulates aldosterone synthesis and release.
🧠 This mechanism operates independently of renin and angiotensin II, allowing rapid K⁺ homeostasis even when volume status is normal.
🧠 Even small increases in serum K⁺ (0.1–0.2 mEq/L) can significantly increase aldosterone secretion — the system is exquisitely sensitive.
🧠 This explains why hyperkalemia in primary adrenal insufficiency is so severe: both glucocorticoid and mineralocorticoid deficiency eliminate K⁺ excretion mechanisms.
🧠 Board pearl: In hyperkalemia with hypoaldosteronism, check for type 4 RTA — the most common cause in diabetics.
Solid White Background
Negative Feedback Mechanisms
⚡ Increased blood pressure → stretches baroreceptors → inhibits sympathetic tone → reduces renin release.
⚡ Volume expansion → increases Na⁺ delivery to macula densa → suppresses renin release.
⚡ Aldosterone-induced Na⁺ retention → volume expansion → atrial natriuretic peptide (ANP) release → opposes RAAS effects by promoting natriuresis and suppressing renin.
⚡ Angiotensin II directly inhibits renin release through AT₁ receptors on juxtaglomerular cells (short-loop negative feedback).
⚡ Board clue: In primary hyperaldosteronism, renin is suppressed due to volume expansion; in secondary hyperaldosteronism, renin is elevated as the primary driver.
Solid White Background
Primary Hyperaldosteronism: Conn Syndrome
📌 Autonomous aldosterone production from an adrenal adenoma (Conn syndrome) or bilateral adrenal hyperplasia.
📌 Classic presentation: hypertension, hypokalemia, metabolic alkalosis, and suppressed plasma renin activity.
📌 The hypokalemia results from excessive K⁺ secretion in exchange for Na⁺ reabsorption; metabolic alkalosis occurs from H⁺ loss accompanying K⁺ secretion.
📌 Screening test: Aldosterone-to-renin ratio (ARR) > 20-30 suggests primary hyperaldosteronism.
📌 Confirmation: Saline suppression test — aldosterone remains elevated despite volume expansion.
📌 Board pearl: Not all patients have hypokalemia; up to 70% maintain normal K⁺ through dietary compensation.
Solid White Background
Secondary Hyperaldosteronism: Appropriate RAAS Activation
📣 Any condition causing decreased renal perfusion activates RAAS appropriately: heart failure, cirrhosis, nephrotic syndrome, renal artery stenosis.
📣 Unlike primary hyperaldosteronism, both renin and aldosterone are elevated — the system is responding normally to perceived volume depletion.
📣 Edematous states (heart failure, cirrhosis) represent a paradox: total body Na⁺ is increased, but effective arterial blood volume is decreased → continued RAAS activation.
📣 Diuretic use commonly causes secondary hyperaldosteronism through volume depletion.
📣 Board distinction: Elevated renin differentiates secondary from primary hyperaldosteronism.
Solid White Background
Hypoaldosteronism: Primary Adrenal Insufficiency
🔸 Addison disease destroys all three zones of the adrenal cortex → deficiency of glucocorticoids, mineralocorticoids, and androgens.
🔸 Loss of aldosterone → Na⁺ wasting, hyperkalemia, hypovolemia, and non-anion gap metabolic acidosis.
🔸 Hyperpigmentation results from increased ACTH (and co-secreted MSH) attempting to stimulate the failing adrenal glands.
🔸 Classic presentation: Hypotension, hyperkalemia, hyponatremia, with elevated ACTH and low cortisol.
🔸 Board pearl: Primary adrenal insufficiency causes both hyperkalemia and hyperpigmentation; secondary (pituitary) insufficiency causes neither.
Solid White Background
Hypoaldosteronism: Hyporeninemic Hypoaldosteronism
🧷 Also called type 4 RTA, this is the most common cause of hypoaldosteronism in adults.
🧷 Diabetic nephropathy damages juxtaglomerular apparatus → decreased renin production → low aldosterone despite hyperkalemia.
🧷 NSAIDs, ACE inhibitors, ARBs, and heparin can all contribute by further suppressing the already impaired RAAS.
🧷 Presents with hyperkalemia and mild non-anion gap metabolic acidosis, typically in diabetic patients with mild-to-moderate CKD.
🧷 Board pearl: Unlike other RTAs, type 4 presents with hyperkalemia, not hypokalemia — the K⁺ distinguishes it immediately.
Solid White Background
Drug Effects on RAAS: ACE Inhibitors and ARBs
📍 ACE inhibitors block angiotensin I → angiotensin II conversion, reducing aldosterone secretion and causing mild hyperkalemia.
📍 ARBs block AT₁ receptors, preventing angiotensin II action while allowing AT₂ receptor activation (which may be cardioprotective).
📍 Both drug classes can precipitate hyperkalemia, especially in CKD, diabetes, or when combined with K⁺-sparing diuretics.
📍 First-dose hypotension occurs from sudden reduction in angiotensin II-mediated vasoconstriction, particularly in volume-depleted patients.
📍 Board pearl: ACE inhibitor cough (from bradykinin accumulation) does not occur with ARBs, making ARBs the alternative for intolerant patients.
Solid White Background
Drug Effects on RAAS: Spironolactone and Eplerenone
🔹 Mineralocorticoid receptor antagonists compete with aldosterone at the receptor level in principal cells.
🔹 Spironolactone also blocks androgen receptors → gynecomastia, decreased libido, menstrual irregularities.
🔹 Eplerenone is more selective for mineralocorticoid receptors → fewer antiandrogenic side effects but more expensive.
🔹 Both cause hyperkalemia by blocking K⁺ secretion; risk increases with CKD, diabetes, or concurrent ACE inhibitor/ARB use.
🔹 Board pearl: Spironolactone improves mortality in heart failure with reduced ejection fraction and is first-line for ascites in cirrhosis.
Solid White Background
Congenital Adrenal Hyperplasias Affecting Aldosterone
⭐ 21-hydroxylase deficiency: Cannot produce mineralocorticoids or glucocorticoids → salt wasting, hyperkalemia, hypotension in newborns.
⭐ 11β-hydroxylase deficiency: Cannot produce cortisol or aldosterone, but 11-deoxycorticosterone accumulates → hypertension despite aldosterone deficiency.
⭐ 17α-hydroxylase deficiency: Cannot produce cortisol or sex hormones, but mineralocorticoid excess → hypertension, hypokalemia, and sexual infantilism.
⭐ Board distinction: 21-hydroxylase deficiency causes hypotension; 11β-hydroxylase and 17α-hydroxylase deficiencies cause hypertension.
Solid White Background
Bartter and Gitelman Syndromes
✅ Both are genetic defects in renal salt transporters causing salt wasting → secondary hyperaldosteronism with paradoxical hypokalemia.
✅ Bartter syndrome: Defect in NKCC2 (thick ascending limb) → mimics loop diuretic effect → severe salt wasting, polyuria, growth retardation.
✅ Gitelman syndrome: Defect in NCC (distal convoluted tubule) → mimics thiazide effect → milder presentation, often diagnosed in adolescence/adulthood.
✅ Both present with hypokalemia, metabolic alkalosis, elevated renin/aldosterone, but normal blood pressure.
✅ Board pearl: Gitelman has hypomagnesemia and hypocalciuria; Bartter has normal Mg²⁺ and hypercalciuria.
Solid White Background
Liddle Syndrome and Apparent Mineralocorticoid Excess
🧠 Liddle syndrome: Gain-of-function mutation in ENaC → constitutively active Na⁺ channels → hypertension, hypokalemia, but LOW aldosterone and renin.
🧠 Apparent mineralocorticoid excess (AME): 11β-HSD2 deficiency → cortisol activates mineralocorticoid receptors → same presentation as Liddle.
🧠 Both conditions cause hypertension with hypokalemia but suppressed aldosterone — distinguishing them from primary hyperaldosteronism.
🧠 Liddle responds to amiloride (blocks ENaC) but not spironolactone; AME responds to spironolactone (blocks MR).
🧠 Board pearl: Young patient with severe hypertension, hypokalemia, and LOW aldosterone → think Liddle or AME, not Conn syndrome.
Solid White Background
Renovascular Disease and RAAS
⚡ Renal artery stenosis reduces perfusion to the affected kidney → chronic renin release → secondary hyperaldosteronism → hypertension.
⚡ Atherosclerotic disease (elderly, smokers) affects the proximal third of the renal artery; fibromuscular dysplasia (young women) affects the distal two-thirds.
⚡ The affected kidney shows atrophy over time due to chronic ischemia, while the contralateral kidney may show compensatory hypertrophy.
⚡ ACE inhibitors can precipitate acute kidney injury by removing angiotensin II-mediated efferent arteriolar constriction in the stenotic kidney.
⚡ Board pearl: Flash pulmonary edema with bilateral renal artery stenosis — loss of RAAS autoregulation causes volume overload.
Solid White Background
Laboratory Evaluation of RAAS
📌 Plasma renin activity (PRA) and plasma aldosterone concentration (PAC) must be interpreted together, not in isolation.
📌 Morning, seated position is standard — posture significantly affects values (supine → lower; upright → higher).
📌 Medications affect results: ACE inhibitors, ARBs, and diuretics increase renin; beta-blockers and NSAIDs suppress renin.
📌 Hypokalemia suppresses aldosterone secretion — K⁺ should be repleted before testing for primary hyperaldosteronism.
📌 Board pearl: Aldosterone-to-renin ratio >20-30 with PAC >15 ng/dL suggests primary hyperaldosteronism.
Solid White Background
Board Question Stem Patterns
📣 Hypertension + hypokalemia + metabolic alkalosis → evaluate aldosterone and renin to distinguish primary from secondary hyperaldosteronism.
📣 Young woman with hypertension and abdominal bruit → fibromuscular dysplasia causing renovascular hypertension.
📣 Diabetic with hyperkalemia and mild acidosis → type 4 RTA from hyporeninemic hypoaldosteronism.
📣 Hypotension + hyperkalemia + hyperpigmentation → primary adrenal insufficiency.
📣 Normotensive patient with hypokalemia and elevated renin/aldosterone → Bartter or Gitelman syndrome.
📣 ACE inhibitor started, creatinine doubles → bilateral renal artery stenosis.
📣 Hypertension + hypokalemia + LOW renin and aldosterone → Liddle syndrome or AME.
Solid White Background
One-Line Recap
🔸 The renin-angiotensin-aldosterone system maintains blood pressure through a cascade from renin (released by renal hypoperfusion, sympathetics, or low NaCl) → angiotensin II → aldosterone → Na⁺ retention and K⁺ secretion, with primary hyperaldosteronism causing low-renin hypertension, secondary hyperaldosteronism showing high renin, and disruptions anywhere in the pathway producing predictable patterns of blood pressure and electrolyte abnormalities.
Solid White Background
bottom of page